Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|April 14, 2014
EMA Sends Roche Findings to European Commission
Author(s)Pharmaceutical Technology Editors
EMA sends its results on Roche investigation of pharmacovigilance non-compliance to the European Commission.
Advertisement
The European Medicines Agency (EMA) has sent its findings from an inquiry into pharmacovigilance non-compliance by Roche Registration to the European Commission. The commission began an infringement procedure against Roche is October 2012 to investigate if the company had failed to comply with pharmacovigilance obligations. A 2012 inspection by the United Kingdom Medicines and Healthcare Products Regulatory Agency had discovered shortcomings in Roche’s pharmacovigilance processes,
EMA’s report summarizes the agency’s findings on the allegations. The European Commission will decide on further action after review the report.
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement